- CH₣2.58bn
- CH₣2.77bn
- €590.58m
Annual income statement for Medacta SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 302 | 363 | 437 | 511 | 591 |
| Cost of Revenue | |||||
| Gross Profit | 214 | 261 | 305 | 348 | 399 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 253 | 304 | 376 | 436 | 500 |
| Operating Profit | 49.4 | 58.8 | 61.5 | 74.4 | 90.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 39.9 | 55.5 | 54.8 | 58.7 | 87.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 37.1 | 51.5 | 46.2 | 47.4 | 72.9 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 37.1 | 51.5 | 46.2 | 47.4 | 72.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 37.1 | 51.5 | 46.2 | 47.4 | 72.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 1.83 | 2.96 | 2.65 | 2.45 | 3.82 |
| Dividends per Share |